NVO - Novo Nordisk A/S
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU Novo Nordisk expects to launch Wegovy® 7.2 mg in a single-dose pen in the EU in Q3 2026 In the STEP UP trial, Wegovy® 7.2 mg demonstrated an average weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss Wegovy® 7.2 mg is already available in the U.S. for adults living with obesity under the brand name Wegovy® HD Bagsværd, Denmark, 22 May 2026 – Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy® 7.2 mg (once-weekly injectable semaglutide 7.2 mg) in a single-dose pen for people living with obesity. Wegovy® 7.2 mg is already available in the EU for adults with obesity, dosed as three injections of 2.4 mg, and is based on results from the STEP UP trial programme.
